Graves' orbitopathy (GO) is a serious, progressive eye condition seen in patients with autoimmune thyroid disease. GO is characterized by inflammation and swelling of soft orbital tissues. Adipose tissue produces cytokine mediators called adipokines. The present study focuses on the relationship between serum levels of selected adipokines in patients with GO, comparing them with the control group, and uniquely describes the effect of high-dose systemic corticosteroids (HDSC) on their levels. For the purposes of this study, we collected blood samples before and after the treatment with HDSC from 60 GO patients and 34 control subjects and measured serum levels of adiponectin, AIF-1, A-FABP and FGF-21. Levels of adiponectin significantly differed among the three study groups (ANOVA p = 0.03). AIF-1 levels were also significantly different among the study groups (ANOVA p < 0.0001). AIF-1 was significantly associated with the presence of GO after adjusting for clinical factors (age, sex, smoking and BMI) and level of TSH (odds ratio 1.003, p < 0.01). This finding could enforce targeting macrophages in treatment strategies for GO since AIF-1 is considered as a marker of their activation.

Department of Clinical Biochemistry University Hospital Olomouc Olomouc Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Czech Republic

Department of Internal Medicine 3 Nephrology Rheumatology and Endocrinology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Czech Republic

Department of Ophthalmology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Czech Republic

Zobrazit více v PubMed

Rotondo Dottore G, Bucci I, Lanzolla G, et al. Genetic profiling of orbital fibroblasts from patients with graves’ orbitopathy. J Clin Endocrinol Metab. 2021;106(5):e2176–e90. PubMed

Lacheta D, Miskiewicz P, Gluszko A, et al. Immunological aspects of graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260. PubMed PMC

Rotondo Dottore G, Torregrossa L, Caturegli P, et al. Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol. 2018;136(6):613–619. PubMed PMC

Dik WA, Virakul S, van Steensel L.. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83–91. PubMed

Li H, Fitchett C, Kozdon K, et al. Independent adipogenic and contractile properties of fibroblasts in graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS One. 2014;9:4. PubMed PMC

Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocr Metab. 2002;87(1):385–392. PubMed

Oh SR, Tung JD, Priel A, et al. Reduction of orbital inflammation following decompression for thyroid-related orbitopathy. Biomed Res Int. 2013;2013:794984. PubMed PMC

Iglesias P, Fidalgo PA, Codoceo R, et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol. 2003;59(5):621–629. PubMed

Ozkaya M, Sahin M, Cakal E, et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest. 2009;32(5):435–439. PubMed

Sieminska L, Niedziolka D, Pillich A, et al. Serum concentrations of adiponectin and resistin in hyperthyroid Graves’ disease patients. J Endocrinol Invest. 2008;31(9):745–749. PubMed

Iglesias P, Diez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine. 2007;40(2):61–70. PubMed

Chen Y, Wu X, Wu R, et al. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism. Sci Rep. 2016;6(1):26174. PubMed PMC

Ren J, Lin Y, Tang J, et al. Allograft inflammatory factor-1 mediates macrophage-induced impairment of insulin signaling in adipocytes. cellular physiology and biochemistry. international journal of experimental cellular physiology, biochemistry, and pharmacology. Cell Physiol Biochem. 2018;47(1):403–413. doi: 10.1159/000489952 PubMed DOI

Sikora M, Kopec B, Piotrowska K, et al. Role of allograft inflammatory factor-1 in pathogenesis of diseases. Immunol Lett. 2020;218:1–4. PubMed

Utans U, Arceci RJ, Yamashita Y, et al. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest. 1995;95(6):2954–2962. PubMed PMC

Fukui M, Tanaka M, Toda H, et al. The serum concentration of allograft inflammatory factor-1 is correlated with metabolic parameters in healthy subjects. Metabolism. 2012;61(7):1021–1025. PubMed

Shu L, Hoo RL, Wu X, et al. A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes. Nat Commun. 2017;8(1):14147. PubMed PMC

Tseng FY, Chen PL, Chen YT, et al. Association between serum levels of adipocyte fatty acid-binding protein and free thyroxine. Medicine (Baltimore). 2015;94(41):e1798. PubMed PMC

Domouzoglou EM, Fisher FM, Astapova I, et al. Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. Endocrinology. 2014;155(5):2031–2040. PubMed PMC

Xiao F, Lin M, Huang P, et al. Elevated serum fibroblast growth factor 21 levels in patients with hyperthyroidism. J Clin Endocrinol Metab. 2015;100(10):3800–3805. PubMed

Lee Y, Park YJ, Ahn HY, et al. Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile. Endocr J. 2013;60(8):977–983. PubMed

Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26. PubMed PMC

Karasek D, Krystynik O, Goldmannova D, et al. Circulating levels of selected adipokines in women with gestational diabetes and type 2 diabetes. Journal of applied biomedicine. 2020;18(2–3):54–60. 10.32725/jab.2020.007 PubMed DOI

Kim BY, Mok JO, Kang SK, et al. The relationship between serum adipocytokines and Graves’ ophthalmopathy: a hospital-based study. Endocr J. 2016;63(5):425–430. PubMed

Autieri MV, Kelemen S, Thomas BA, et al. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation. 2002;106(17):2218–2223. PubMed

Zhao YY, Yan DJ, Chen ZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013;284(1–2):75–83. PubMed

Naselli A, Moretti D, Regalbuto C, et al. Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves’ ophthalmopathy to parenteral corticosteroids. Front Endocrinol (Lausanne). 2020;11:997. PubMed PMC

Lanzolla G, Vannucchi G, Ionni I, et al. Cholesterol serum levels and use of statins in graves’ orbitopathy: a new starting point for the therapy. Front Endocrinol (Lausanne). 2020;10:933. PubMed PMC

Ayabe R, Rootman DB, Hwang CJ, et al. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415–419. PubMed

Spurna J, Karasek D, Kubickova V, et al. Relationship of selected adipokines with markers of vascular damage in patients with type 2 diabetes. Metab Syndr Relat Disord. 2018;16(5):246–253. PubMed

Yun KE, Kim SM, Choi KM, et al. Association between adipocyte fatty acid-binding protein levels and childhood obesity in Korean children. Metabolism. 2009;58(6):798–802. PubMed

Bande AR, Kalra P, Dharmalingam M, et al. Serum fibroblast growth factor 21 levels in patients with hyperthyroidism and its association with body fat percentage. Indian J Endocrinol Metab. 2019;23(5):557–562. PubMed PMC